Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > SSRX > Summary

More on SSRX

3SBio Inc.
(SSRX)

10.18USD   Down 0.07 (0.68%)   
At 2:30AM IST
 3SBio Inc. (NasdaqNM:SSRX) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Last Trade: 10.18USD
Trade Time:2:30AM IST
Change:Down 0.07 (0.68%) 
Prev Close:10.25
Open:10.25
Bid:9.18 x 200
Ask:N/A
1y Target Est:14.75
Day's Range:10.15 - 10.35
52wk Range:4.18 - 14.45
Volume:165,450
Avg Vol (3m):98,919
Market Cap:219.06M
P/E (ttm):N/A
EPS (ttm):N/A
Div & Yield:N/A (N/A%)
Add SSRX to Portfolio   Download Data

HEADLINES

 
•3SBio Gains China Rights to Another Dialysis Drug - Seeking Alpha  - Tue 1:13PM
•3SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia - PR Newswire  - Mon, Feb 8
•3SBio Inc. to Report 2009 Fourth Quarter and Full Year Results on February 11, 2010 - PR Newswire  - Tue, Jan 26
•2 Stocks Hitting Low Notes - Motley Fool  - Tue, Jan 26
•AMAG Pharma Guides on Feraheme - Zacks.com  - Mon, Jan 11
•China Biotech Week in Review: New Investments for a New Year - Seeking Alpha  - Sun, Jan 10
•3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) - PR Newswire  - Fri, Jan 8
•Prospecting for Stocks: QLT - Motley Fool  - Thu, Dec 17
•The Wrong Way to Invest in China - Motley Fool  - Fri, Dec 11
•Build Your Fortune With These Winners - Motley Fool  - Fri, Dec 4
•Biotech Bargains for Your Portfolio - Motley Fool  - Fri, Nov 27
•3SBIO INC Earnings Call scheduled for 8:00 am ET today - CCBN  - Fri, Nov 13
•3SBio Inc. Announces Unaudited Third Quarter 2009 Results - PR Newswire  - Fri, Nov 13
» More Headlines for SSRX...

ANALYST

 
EPS Est (next year) (Dec-09) :0.56
EPS Est (in 2 years) (Dec-10) :0.65
Avg Rec (current)*:1.5
PEG Ratio:1.50
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
3SBio Inc., a biotechnology company, focuses on the research, development, manufacture, and marketing of biopharmaceutical products primarily in the People’s Republic of China.

» Full Company Profile